LABQUALITY

External Quality Assessment Scheme

Parvovirus (B19), antibodies
Round 1, 2023

Specimens
Please find enclosed 3 human plasma or serum samples S001, S002 and S003, each 0.4 mL.

Caution
Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Examinations
Parvovirus (B19) IgG antibodies
Parvovirus (B19) IgM antibodies
Parvovirus (B19) IgG avidity
Clinical interpretation

Storage and use
After arrival, the samples should be stored at +2…8 °C, and used as soon as possible, preferably within a week. The samples are ready for use. Analyse as patient samples.

Result reporting
Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator. All reported examinations will be scored.

S001

LQ773923011

S002

LQ773923012

S003

LQ773923013

LABQUALITY

Client report

	No of participants	No of responded participants	Response percentage
Parvovirus B19, antibodies, March, 1-2023	55	52	94.5 %

Summary

Overall success rate by samples

- Sample S001 Own success rate 100 %
- Sample S002 Own success rate 100 %
- Sample S003 Own success rate 100 %
- Average: Own success rate 100 %

Legend: ■ Sample AVR success rate ■ Own success rate ■ Target

Success rate history

- Round 2022-4 Own success rate 100 %
- Round 2022-2 Own success rate 100 %
- Round 2022-1 Own success rate 100 %
- Round 2021-4 Own success rate 100 %
- Round 2021-2 Own success rate 100 %
- Round 2021-1 Own success rate 100 %
- Round 2020-4 Own success rate 100 %
- Round 2020-2 Own success rate 100 %

Legend: ■ Round AVR success rate ■ Own success rate ■ Target

Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	8	8	100 %	0 %	100 %
Sample S002	8	8	100 %	0.5 %	99.5 %
Sample S003	8	8	100 %	2.6 %	97.4 %
Average:			100 %	1 %	99 %

| History		Test nr.	Own success rate	Difference	AVR success rate
	Round 2022-4	1-1	100 %	0.9 %	99.1 %
	Round 2022-2	1-1	100 %	1.2 %	98.8 %
	Round 2022-1	1-1	100 %	0.5 %	99.5 %
	Round 2021-4	1-1	100 %	0.4 %	99.6 %
	Round 2021-2	1-1	100 %	0 %	100 %
	Round 2021-1	1-1	100 %	0.8 %	99.2 %
	Round 2020-4	1-1	100 %	2.7 %	97.3 %
	Round 2020-2	1-1	100 %	0.8 %	99.2 %

LABQUALITY

Sample S001

Sample S001 success rate

Sample S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	0 %	100 %	53
	ParvAbG	2	2	100 %	0 %	100 %	53
	ParvAbM	2	2	100 %	0 %	100 %	52
Total:		8	8	100 %	0 %	100 %	158

Sample S001 Clinical interpretation

18.9 %
n=10

81.1 %
n=43

■ Old immunity
■ Laboratory does not give interpretation

| Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	Own score	Max score	Own success rate	Difference	AVR success rate
	⊙ Old immunity		43		4	4	100 %	0 %	100 %
	Laboratory does not give interpretation		10		-				-
	Total:		53		4	4	100 %	0 %	100 %

LABQUALITY

Sample S001 ParvAbG

100.0 %
n=53

■ Positive

Sample S001 ParvAbM

100.0 %
n=52

■ Negative

OWN DEVICE: LIAISON

ParvAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	◉ Positive		53		2	2	100 %	0 %	100 %
		DiaSorin Biotrin Parvovirus B19 IgG EIA		4					
		◉ DiaSorin Liaison Parvovirus IgG B19		35					
		Euroimmun Parvovirus B19 IgG ELISA		4					
		In-house Parvovirus B19 IgG EIA		2					
		NovaTec NovaLisa Parvovirus B19 IgG ELISA		2					
		Orgentec Alegria Anti-Parvovirus B19 IgG		1					
		Siemens Novagnost Parvovirus B19 IgG		1					
		Vircell VirClia Parvovirus IgG Monotest		2					
		Virion/Serion Parvovirus B19 IgG Serion ELISA classic		2					
	Total:		53		2	2	100 %	0 %	100 %

OWN DEVICE: LIAISON

ParvAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	◉ Negative		52		2	2	100 %	0 %	100 %
		DiaSorin Biotrin Parvovirus B19 IgM EIA		4					
		◉ DiaSorin Liaison Parvovirus IgM B19		35					
		Euroimmun Parvovirus B19 IgM ELISA		3					
		In-house Parvovirus B19 IgM EIA		2					
		NovaTec NovaLisa Parvovirus B19 IgM ELISA		2					
		Orgentec Alegria Anti-Parvovirus B19 IgM		1					
		Siemens Novagnost Parvovirus B19 IgM		1					
		Vircell VirClia Parvovirus IgM Monotest		2					
		Virion/Serion Parvovirus B19 IgM Serion ELISA classic		2					
	Total:		52		2	2	100 %	0 %	100 %

Sample S002

Sample S002 success rate

Clinical interpretation Own success rate 100 %

ParvAbG Own success rate 100 %

ParvAbM Own success rate 100 %

ParvAvi Not responded

■ Sample AVR success rate   ■ Own success rate   ■ Target

Sample S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	0 %	100 %	53
	ParvAbG	2	2	100 %	1.9 %	98.1 %	53
	ParvAbM	2	2	100 %	0 %	100 %	52
	ParvAvi	-	-	-	-	-	1
Total:		8	8	100 %	0.5 %	99.5 %	159

Sample S002 Clinical interpretation

20.8 %
n=11

79.2 %
n=42

■ Acute/recent infection
■ Laboratory does not give interpretation

Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	Own score	Max score	Own success rate	Difference	AVR success rate
	⊙ Acute/recent infection		42		4	4	100 %	0 %	100 %
		New sample requested		8	-	-			
	Laboratory does not give interpretation		11		-				-
	Total:		53		4	4	100 %	0 %	100 %

LABQUALITY

Sample S002 ParvAbG

1.9 %
n=1

98.1 %
n=52

■ Borderline ■ Positive

Sample S002 ParvAbM

100.0 %
n=52

■ Positive

Sample S002 ParvAvi

100.0 %
n=1

■ Weak avidity

OWN DEVICE: LIAISON

| ParvAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Borderline		1		-				0 %
		DiaSorin Liaison Parvovirus IgG B19		1					
	◉ Positive		52		2	2	100 %	0 %	100 %
		DiaSorin Biotrin Parvovirus B19 IgG EIA		4					
		◉ DiaSorin Liaison Parvovirus IgG B19		34					
		Euroimmun Parvovirus B19 IgG ELISA		4					
		In-house Parvovirus B19 IgG EIA		2					
		NovaTec NovaLisa Parvovirus B19 IgG ELISA		2					
		Orgentec Alegria Anti-Parvovirus B19 IgG		1					
		Siemens Novagnost Parvovirus B19 IgG		1					
		Vircell VirClia Parvovirus IgG Monotest		2					
		Virion/Serion Parvovirus B19 IgG Serion ELISA classic		2					
	Total:		53		2	2	100 %	1.9 %	98.1 %

OWN DEVICE: LIAISON

ParvAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	◉ Positive		52		2	2	100 %	0 %	100 %
		DiaSorin Biotrin Parvovirus B19 IgM EIA		4					
		◉ DiaSorin Liaison Parvovirus IgM B19		35					
		Euroimmun Parvovirus B19 IgM ELISA		3					
		In-house Parvovirus B19 IgM EIA		2					
		NovaTec NovaLisa Parvovirus B19 IgM ELISA		2					
		Orgentec Alegria Anti-Parvovirus B19 IgM		1					
		Siemens Novagnost Parvovirus B19 IgM		1					
		Vircell VirClia Parvovirus IgM Monotest		2					
		Virion/Serion Parvovirus B19 IgM Serion ELISA classic		2					
	Total:		52		2	2	100 %	0 %	100 %

ParvAvi	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Weak avidity		1		-				-

	In-house Parvovirus B19 IgG Avi EIA		1					
	Total:		1		-	-	-	-	

Sample S003

Sample S003 success rate

Legend: ■ Sample AVR success rate ■ Own success rate ■ Target

Sample S003 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	2.3 %	97.7 %	53
	ParvAbG	2	2	100 %	1.9 %	98.1 %	53
	ParvAbM	2	2	100 %	3.8 %	96.2 %	52
Total:		8	8	100 %	2.6 %	97.4 %	158

Sample S003 Clinical interpretation

Legend: ■ Old immunity ■ Acute/recent infection ■ Laboratory does not give interpretation

Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	Own score	Max score	Own success rate	Difference	AVR success rate
	⦿ Old immunity		42		4	4	100 %	0 %	100 %
	Acute/recent infection		1		-				0 %
	Laboratory does not give interpretation		10		-				-
	Total:		53		4	4	100 %	2.3 %	97.7 %

LABQUALITY

Sample S003 ParvAbG

1.9 %
n=1

98.1 %
n=52

- Borderline   - Positive

Sample S003 ParvAbM

1.9 %
n=1

1.9 %
n=1

96.2 %
n=50

- Negative   - Borderline   - Positive

OWN DEVICE: LIAISON

ParvAbG	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	Borderline		1		-				0 %
		DiaSorin Liaison Parvovirus IgG B19		1					
	⊙ Positive		52		2	2	100 %	0 %	100 %
		DiaSorin Biotrin Parvovirus B19 IgG EIA		4					
		⊙ DiaSorin Liaison Parvovirus IgG B19		34					
		Euroimmun Parvovirus B19 IgG ELISA		4					
		In-house Parvovirus B19 IgG EIA		2					
		NovaTec NovaLisa Parvovirus B19 IgG ELISA		2					
		Orgentec Alegria Anti-Parvovirus B19 IgG		1					
		Siemens Novagnost Parvovirus B19 IgG		1					
		Vircell VirClia Parvovirus IgG Monotest		2					
		Virion/Serion Parvovirus B19 IgG Serion ELISA classic		2					
	Total:		53		2	2	100 %	1.9 %	98.1 %

OWN DEVICE: LIAISON

ParvAbM	Interpretation	Method	Interpretation count	Method count	Own score	Max score	Own success rate	Difference	AVR success rate
	⊙ Negative		50		2	2	100 %	0 %	100 %
		DiaSorin Biotrin Parvovirus B19 IgM EIA		4					
		⊙ DiaSorin Liaison Parvovirus IgM B19		35					
		Euroimmun Parvovirus B19 IgM ELISA		3					
		In-house Parvovirus B19 IgM EIA		2					
		NovaTec NovaLisa Parvovirus B19 IgM ELISA		2					
		Orgentec Alegria Anti-Parvovirus B19 IgM		1					
		Siemens Novagnost Parvovirus B19 IgM		1					
		Virion/Serion Parvovirus B19 IgM Serion ELISA classic		2					
	Borderline		1		-				0 %
		Vircell VirClia Parvovirus IgM Monotest		1					
	Positive		1		-				0 %
		Vircell VirClia Parvovirus IgM Monotest		1					
	Total:		52		2	2	100 %	3.8 %	96.2 %

Report Info

PARTICIPANTS

Altogether 55 laboratories from 17 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button ⊙. In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

LABQUALITY

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Parvovirus B19, antibodies, March, 1-2023	55	52	94.5 %

Summary

Overall success rate by samples

Sample S001 success rate 100 %
Sample S002 success rate 99.5 %
Sample S003 success rate 97.4 %
Average: success rate 99 %

■ Sample AVR success rate   ■ Target

Summary	AVR success rate
Sample S001	100 %
Sample S002	99.5 %
Sample S003	97.4 %
Average:	99 %

Sample S001

Sample S001 success rate

Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	100 %	53
	ParvAbG	100 %	53
	ParvAbM	100 %	52
Total:		100 %	158

Sample S001 Clinical interpretation

18.9 %
n=10

81.1 %
n=43

- Old immunity
- Laboratory does not give interpretation

Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Old immunity		43		100 %	4	
	Laboratory does not give interpretation		10		-	-	
	Total:		53		100 %		

LABQUALITY

Sample S001 ParvAbG

100.0 %
n=53

Sample S001 ParvAbM

100.0 %
n=52

■ Positive

■ Negative

| ParvAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		53		100 %	2
		DiaSorin Biotrin Parvovirus B19 IgG EIA		4		
		DiaSorin Liaison Parvovirus IgG B19		35		
		Euroimmun Parvovirus B19 IgG ELISA		4		
		In-house Parvovirus B19 IgG EIA		2		
		NovaTec NovaLisa Parvovirus B19 IgG ELISA		2		
		Orgentec Alegria Anti-Parvovirus B19 IgG		1		
		Siemens Novagnost Parvovirus B19 IgG		1		
		Vircell VirClia Parvovirus IgG Monotest		2		
		Virion/Serion Parvovirus B19 IgG Serion ELISA classic		2		
	Total:		53		100 %	

ParvAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		52		100 %	2
		DiaSorin Biotrin Parvovirus B19 IgM EIA		4		
		DiaSorin Liaison Parvovirus IgM B19		35		
		Euroimmun Parvovirus B19 IgM ELISA		3		
		In-house Parvovirus B19 IgM EIA		2		
		NovaTec NovaLisa Parvovirus B19 IgM ELISA		2		
		Orgentec Alegria Anti-Parvovirus B19 IgM		1		
		Siemens Novagnost Parvovirus B19 IgM		1		
		Vircell VirClia Parvovirus IgM Monotest		2		
		Virion/Serion Parvovirus B19 IgM Serion ELISA classic		2		
	Total:		52		100 %	

LABQUALITY

Sample S002

Sample S002 success rate

Clinical interpretation success rate 100 %
ParvAbG success rate 98.1 %
ParvAbM success rate 100 %
ParvAvi Not scored

Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	100 %	53
	ParvAbG	98.1 %	53
	ParvAbM	100 %	52
	ParvAvi	-	1
Total:		99.5 %	159

Sample S002 Clinical interpretation

20.8 %
n=11

79.2 %
n=42

- ■ **Acute/recent infection**
- ■ **Laboratory does not give interpretation**

Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Acute/recent infection		42		100 %	4	
		New sample requested		8	-		-
	Laboratory does not give interpretation		11		-	-	
	Total:		53		100 %		

Sample S002 ParvAbG

1.9 %
n=1

98.1 %
n=52

■ Borderline ■ Positive

Sample S002 ParvAbM

100.0 %
n=52

■ Positive

Sample S002 ParvAvi

100.0 %
n=1

■ Weak avidity

ParvAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Borderline		1		0 %	0
		DiaSorin Liaison Parvovirus IgG B19		1		
	Positive		52		100 %	2
		DiaSorin Biotrin Parvovirus B19 IgG EIA		4		
		DiaSorin Liaison Parvovirus IgG B19		34		
		Euroimmun Parvovirus B19 IgG ELISA		4		
		In-house Parvovirus B19 IgG EIA		2		
		NovaTec NovaLisa Parvovirus B19 IgG ELISA		2		
		Orgentec Alegria Anti-Parvovirus B19 IgG		1		
		Siemens Novagnost Parvovirus B19 IgG		1		
		Vircell VirClia Parvovirus IgG Monotest		2		
		Virion/Serion Parvovirus B19 IgG Serion ELISA classic		2		
	Total:		53		98.1 %	

ParvAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Positive		52		100 %	2
		DiaSorin Biotrin Parvovirus B19 IgM EIA		4		
		DiaSorin Liaison Parvovirus IgM B19		35		
		Euroimmun Parvovirus B19 IgM ELISA		3		
		In-house Parvovirus B19 IgM EIA		2		
		NovaTec NovaLisa Parvovirus B19 IgM ELISA		2		
		Orgentec Alegria Anti-Parvovirus B19 IgM		1		
		Siemens Novagnost Parvovirus B19 IgM		1		
		Vircell VirClia Parvovirus IgM Monotest		2		
		Virion/Serion Parvovirus B19 IgM Serion ELISA classic		2		
	Total:		52		100 %	

ParvAvi	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Weak avidity		1		-	-
		In-house Parvovirus B19 IgG Avi EIA		1		
	Total:		1			

Sample S003

Sample S003 success rate

Clinical interpretation success rate 97.7 %

ParvAbG success rate 98.1 %

ParvAbM success rate 96.2 %

Sample S003 results	Responded	AVR success rate	Count
	Clinical interpretation	97.7 %	53
	ParvAbG	98.1 %	53
	ParvAbM	96.2 %	52
Total:		97.4 %	158

Sample S003 Clinical interpretation

18.9 %
n=10

1.9 %
n=1

79.2 %
n=42

- Old immunity
- Acute/recent infection
- Laboratory does not give interpretation

Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Old immunity		42		100 %	4	
	Acute/recent infection		1		0 %	0	
	Laboratory does not give interpretation		10		-	-	
	Total:		53		97.7 %		

LABQUALITY

Sample S003 ParvAbG

1.9 %
n=1

98.1 %
n=52

Sample S003 ParvAbM

1.9 %
n=1

1.9 %
n=1

96.2 %
n=50

■ Borderline ■ Positive   ■ Negative ■ Borderline ■ Positive

ParvAbG	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Borderline		1		0 %	0
		DiaSorin Liaison Parvovirus IgG B19		1		
	Positive		52		100 %	2
		DiaSorin Biotrin Parvovirus B19 IgG EIA		4		
		DiaSorin Liaison Parvovirus IgG B19		34		
		Euroimmun Parvovirus B19 IgG ELISA		4		
		In-house Parvovirus B19 IgG EIA		2		
		NovaTec NovaLisa Parvovirus B19 IgG ELISA		2		
		Orgentec Alegria Anti-Parvovirus B19 IgG		1		
		Siemens Novagnost Parvovirus B19 IgG		1		
		Vircell VirClia Parvovirus IgG Monotest		2		
		Virion/Serion Parvovirus B19 IgG Serion ELISA classic		2		
	Total:		53		98.1 %	

ParvAbM	Interpretation	Method	Interpretation count	Method count	AVR success rate	Interpretation Score
	Negative		50		100 %	2
		DiaSorin Biotrin Parvovirus B19 IgM EIA		4		
		DiaSorin Liaison Parvovirus IgM B19		35		
		Euroimmun Parvovirus B19 IgM ELISA		3		
		In-house Parvovirus B19 IgM EIA		2		
		NovaTec NovaLisa Parvovirus B19 IgM ELISA		2		
		Orgentec Alegria Anti-Parvovirus B19 IgM		1		
		Siemens Novagnost Parvovirus B19 IgM		1		
		Virion/Serion Parvovirus B19 IgM Serion ELISA classic		2		
	Borderline		1		0 %	0
		Vircell VirClia Parvovirus IgM Monotest		1		
	Positive		1		0 %	0
		Vircell VirClia Parvovirus IgM Monotest		1		
	Total:		52		96.2 %	

Report Info

PARTICIPANTS

Altogether 55 laboratories from 17 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button ◉. In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

LABQUALITY

External Quality Assessment Scheme
Parvovirus B19, antibodies
Round 1, 2023

Specimens
Samples of this EQA round were human plasma or serum, each of which originated from a single donor. Based on the pre-testing and the results obtained in the round, the samples were homogeneous, stable and suitable for the external quality assessment scheme. The materials were sent without temperature control packaging.

The expected results were as follows:

Sample S001 (LQ773923011)
Parvovirus IgG   Positive
Parvovirus IgM   Negative
Clinical interpretation   Old immunity

Sample S002 (LQ773923012)
Parvovirus IgG   Positive
Parvovirus IgM   Positive
Clinical interpretation   Acute/recent infection

Sample S003 (LQ773923013)
Parvovirus IgG   Positive
Parvovirus IgM   Negative
Clinical interpretation   Old immunity

Pre-test methods: In-house Parvovirus B19 IgG EIA and DiaSorin Biotrin Parvovirus B19 IgM EIA.

Report info
Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – EQA Coordinator
The round included two old immunity samples (S001 and S003) and one acute/recent infection sample (S002). Participants performed very well in this EQA round. However, a few deviating test results were also reported.

One deviating borderline IgG result was reported for both samples S002 and S003. Also, one deviating borderline and one positive IgM test result was reported for sample S003. Deviating test results had been reported using the same commercial test methods. The false positive IgM result also led to a false clinical interpretation. All other test results and clinical interpretations were reported correctly/as expected.

Exceptions in scoring
No exceptions.

End of report

FINAS
Finnish Accreditation Service
PT02 (EN ISO/IEC 17043)

Quality Management
DQS
ISO 9001:2015